Showing results (81-90 of 117) with videos related to
Sort By:
Pageof 12
Epigenetics|April 4, 2014
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancerShashwat Sharad, Lakshmi Ravindranath, Michael C Haffner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.Experimental Cell Research|January 18, 2006
Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell linesYongpeng Gu, Hongzhen Li, Jun Miki, et al.Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.Journal of Clinical Immunology|May 28, 2004
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patientsMichael M Woll, Christine M Fisher, Gayle B Ryan, et al.Genes & Cancer|September 16, 2014
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancerAnshu Rastogi, Shyh-Han Tan, Ahmed A Mohamed, et al.The Journal of Urology|September 20, 2008
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volumeEric J Whitman, Jack Groskopf, Amina Ali, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survivalJoseph R Sterbis, Chunling Gao, Bungo Furusato, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patientsMatthew T Hueman, Zia A Dehqanzada, Thomas E Novak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2003
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomyChristopher L Amling, Robert H Riffenburgh, Leon Sun, et al.Pageof 12